Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058994 · ClinicalTrials.gov registry record · Phase 3
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
A Phase 3 study of Macular Degeneration and Maculopathy, Age-Related, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00058994 is a Phase 3 study of Macular Degeneration and Maculopathy, Age-Related that has completed, run by Alcon Research. The trial reports 1 study location across 1 state.
The verdict
NCT00058994, a Phase 3 study of Macular Degeneration and Maculopathy, Age-Related, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.
Conditions Studied
Interventions
- DRUG anecortave acetate
Study Locations (1)
Texas
- South America - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-03 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058994
The ClinicalTrials.gov registry entry for NCT00058994 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which anecortave acetate is the first listed.
NCT00058994 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00058994 about?
NCT00058994 is a clinical study titled "An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD". The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.
What is the current status of trial NCT00058994?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-03. Estimated completion is 2006-11.
What conditions does trial NCT00058994 study?
This clinical trial studies the following conditions: Macular Degeneration, Maculopathy, Age-Related.
What interventions are being tested in trial NCT00058994?
The interventions under investigation include: anecortave acetate (DRUG).
Who is sponsoring clinical trial NCT00058994?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00058994 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
COMPLETED · Phase 3
-
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
COMPLETED · Phase 3
-
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
COMPLETED · Phase 3
-
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
COMPLETED · Phase 3
-
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
COMPLETED · Phase 3
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.